Pfizer Inc.
Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

Abstract:

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. ##STR00001##